FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.
A globally recognized oncology expert, Dr. Armitage currently serves as the Joe Shapiro Professor of Medicine, Division of Oncology and Hematology at the University of Nebraska Medical Center (UNMC), where he has been on faculty since 1982. Dr. Armitage has served as President of both the American Society for Transplantation and Cellular Therapy (ASTCT) and the American Society of Clinical Oncology (ASCO).
“We are deeply honored to have Dr. Armitage join Syncromune’s Scientific Advisory Board as chair,” stated Eamonn Hobbs, President and CEO of Syncromune. “We are confident that his deep clinical expertise and profound contributions to the advancement of cancer treatment will be invaluable to Syncromune’s clinical development programs and a critical component to driving our ultimate success in treating patients living with cancer.”
“We are very honored and humbled to have Dr. Armitage lead our Scientific Advisory Board,” stated Charles Link, M.D., Executive Chairman of Syncromune. “His career has been focused on helping patients with cancer through difficult times and his patient-centered focus will be central in our efforts to advance our promising therapy for patients in greatest need.”
“I am excited to be working with my distinguished colleagues on Syncromune’s Scientific Advisory Board,” stated Dr. Armitage. “I look forward to contributing to the advancement of this novel program that has the potential to revolutionize the treatment of metastatic castrate-resistant prostate cancer.”
Since joining UNMC in 1982, Dr. Armitage has held several positions, including serving as Vice Chairman of the Department of Medicine (1982-90), Chief of the Division of Oncology/Hematology (1986-89), Chairman of the Department of Internal Medicine (1990-99), and Dean of the College of Medicine (2000-03).
He is a member and the Editor-in-Chief of The ASCO Post. He is a Fellow of the American College of Physicians, the Royal College of Physicians, American Association for Advancement of Sciences, ASTCT, and ASCO. He has authored or co-authored more than 600 articles and 100 book chapters and is the editor/co-editor of 27 books.
Throughout his remarkable career, Dr. Armitage has received numerous honors from around the world including the Claude Jacquillat Award for achievement in Clinical Oncology, Paris; the San Salvatore Foundation Research Award, Switzerland; the Richard and Hinda Rosenthal Foundation Research Award from the American Association of Cancer Research; the Heath Memorial Award from the University of Texas MD Anderson Cancer Center; the Robert A. Kyle Award from the Mayo Clinic; election to the Association of American Physicians; and the American Society of Clinical Oncology’s Special Recognition Award for major accomplishments in the fields of oncology and hematology.
About Syncromune®
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform technology optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially curative efficacy. The company is currently developing SYNC-T™, a novel combination drug/device treatment platform. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated Phase 1 trials. Syncromune is headquartered in Fort Lauderdale, FL, USA. For more information, please visit www.syncromune.com.
About SYNC-T™
Syncromune® is developing SYNC-T™, a disruptive personalized in situ combination drug/device platform designed to educate T cells and stimulate the immune system to treat metastatic solid tumors throughout the body. SYNC-T utilizes a combination approach of tumor activation and targeted delivery, aiming to synchronize the timing and location of tumor antigen release with the functional activation of immune cells. To achieve tumor activation, a portion of a target tumor is lysed to generate immunogenic cell death and the release of Damage Associated Molecular Patterns (DAMPs) and tumor neoantigens, changing the tumor microenvironment by creating an in situ vaccine. The second component of the platform, targeted delivery, involves the intratumoral/locoregional infusion of a proprietary fixed-dose combination drug with 4 active ingredients into the lysed portion of the tumor. This is designed to activate the immune system and combat immune suppression, resulting in patient-specific T cell education. The expansion of anti-cancer specific T cells can recognize and destroy cancer in the treated tumor as well as in metastases throughout the body.
This press release includes forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained in this press release or expressed orally in connection herewith that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, forward-looking statements can be identified by phrases such as “plans,” “intends,” “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Accordingly, you should not place undue reliance on our forward-looking statements. The forward-looking statements contained in this press release or expressed orally in connection herewith are made only as of the date of this press release and we undertake no obligation to update the forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law. None of Syncromune, Inc., its affiliates or their respective directors, officers, employees or agents gives any representation or warranty, express or implied, as to: (i) the achievement or reasonableness of future projections, management targets, estimates or prospects contained in this press release; or (ii) the accuracy or completeness of any information contained in this press release, any other written information or oral information provided in connection herewith or any data that any of them generates. This press release was prepared by us for informational purposes only and does not constitute an offer, or solicitation of an offer, to sell any securities at any time. None of Syncromune’s securities have been registered under the Securities Act of 1933, as amended, or any state securities law. Such securities have not been approved or disapproved by the Securities and Exchange Commission or by any state securities regulatory authority, nor has the Securities and Exchange Commission or any such state authority passed on the accuracy or adequacy of this press release. Any representation to the contrary is a criminal offense. Some of the information contained in this press release may be derived from information provided by industry sources. We believe that such information is accurate and that the sources from which it has been obtained are reliable; however, we cannot guarantee the accuracy of such information and have not independently verified such information.
